Kim Jung Han, Jeong Soo Young, Jang Hyun Joo, Park Sung Taek, Kim Hyeong Su
Division of Hemato-Oncology, Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, College of Medicine, Hallym University, Seoul, South Korea.
Department of Obstetrics and Gynecology, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, College of Medicine, Hallym University, Seoul, South Korea.
Front Oncol. 2021 Oct 19;11:762528. doi: 10.3389/fonc.2021.762528. eCollection 2021.
The fibroblast growth factor-4 receptor (FGFR4) is a member of receptor tyrosine kinase. The Gly388Arg polymorphism in the transmembrane domain of the receptor has been shown to increase genetic susceptibility to cancers. However, its prognostic impact in cancer patients still remains controversial. Herein, we performed this meta-analysis to evaluate the clinicopathological and prognostic impacts of the Gly388Arg polymorphism in patients with cancer. We carried out a computerized extensive search using PubMed, Medline, and Ovid Medline databases up to July 2021. From 44 studies, 11,574 patients were included in the current meta-analysis. Regardless of the genetic models, there was no significant correlation of the Gly388Arg polymorphism with disease stage 3/4. In the homozygous model (Arg/Arg vs. Gly/Gly), the Arg/Arg genotype tended to show higher rate of lymph node metastasis compared with the Gly/Gly genotype (odds ratio = 1.21, 95% confidence interval (CI): 0.99-1.49, p = 0.06). Compared to patients with the Arg/Gly or Arg/Arg genotype, those with the Gly/Gly genotype had significantly better overall survival (hazard ratios (HR) = 1.19, 95% CI: 1.05-1.35, p 0.006) and disease-free survival (HR = 1.25, 95% CI: 1.03-1.53, p = 0.02). In conclusion, this meta-analysis showed that the Gly388Arg polymorphism was significantly associated with worse prognosis in cancer patients. Our results suggest that this polymorphism may be a valuable genetic marker to identify patients at higher risk of recurrence or mortality.
成纤维细胞生长因子-4受体（FGFR4）是受体酪氨酸激酶家族的一员。该受体跨膜结构域中的Gly388Arg多态性已被证明会增加癌症的遗传易感性。然而，其对癌症患者的预后影响仍存在争议。在此，我们进行了这项荟萃分析，以评估Gly388Arg多态性对癌症患者临床病理和预后的影响。我们使用PubMed、Medline和Ovid Medline数据库进行了计算机化广泛检索，检索截至2021年7月。从44项研究中，11574例患者被纳入当前的荟萃分析。无论遗传模型如何，Gly388Arg多态性与疾病3/4期均无显著相关性。在纯合子模型（Arg/Arg与Gly/Gly）中，与Gly/Gly基因型相比，Arg/Arg基因型的淋巴结转移率往往更高（优势比=1.21，95%置信区间（CI）：0.99-1.49，p=0.06）。与Arg/Gly或Arg/Arg基因型的患者相比，Gly/Gly基因型的患者总生存期显著更好（风险比（HR）=1.19，95%CI：1.05-1.35，p=0.006），无病生存期也显著更好（HR=1.25，95%CI：1.03-1.53，p=0.02）。总之，这项荟萃分析表明，Gly388Arg多态性与癌症患者预后较差显著相关。我们的结果表明，这种多态性可能是一种有价值的遗传标志物，可用于识别复发或死亡风险较高的患者。
